Menu Search
Equities

Bonesupport Holding AB

BONEX:STO

Bonesupport Holding AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)352.20
  • Today's Change6.20 / 1.79%
  • Shares traded60.82k
  • 1 Year change+110.77%
  • Beta0.9038
Data delayed at least 15 minutes, as of Nov 22 2024 11:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform3
Hold0
Sell1
Strong Sell0

Share price forecast in SEK

The 4 analysts offering 12 month price targets for Bonesupport Holding AB have a median target of 382.50, with a high estimate of 417.00 and a low estimate of 280.00. The median estimate represents a 10.55% increase from the last price of 346.00.
High20.5%417.00
Med10.5%382.50
Low-19.1%280.00

Dividends

Dividend information is not available for Bonesupport Holding AB.
Div growth (TTM)--
More ▼

Earnings history & estimates in SEK

Bonesupport Holding AB reported annual 2023 earnings of 3.74 per share on Feb 15, 2024.
Average growth rate+29.17%
More ▼

Revenue history & estimates in SEK

Bonesupport Holding AB (publ) had 3rd quarter 2024 revenues of 237.50m. This bettered the 232.00m consensus of the 2 analysts covering the company. This was 98.35% above the prior year's 3rd quarter results.
Average growth rate+10.80%
Bonesupport Holding AB (publ) had revenues for the full year 2023 of 591.08m. This was 79.76% above the prior year's results.
Average growth rate+42.07%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.